Adenosine deaminase gene therapy
Latest Information Update: 29 Aug 2007
At a glance
- Originator Genetic Therapy; National Institute of Health and Nutrition
- Class Gene therapies
- Mechanism of Action Adenosine deaminase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adenosine deaminase deficiency
Most Recent Events
- 20 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Metabolic disorders therapeutic trials section ,
- 29 Apr 2003 A study has been added to the Metabolic disorders therapeutic trials section
- 03 Oct 2002 Suspended - Phase-I for Adenosine deaminase deficiency in Italy (Infusion)